Richard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY

Size: px
Start display at page:

Download "Richard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY"

Transcription

1 Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller is approved by the California Board of Registered Nursing, Provider Number 4229, for 1.0 contact hours. RNs outside California must verify with their licensing agency for approval of this course. Richard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY Rebecca A. Clark-Snow, RN, BSN, OCN Oncology Clinical Nurse Coordinator University of Kansas Cancer Center Westwood, KS Medical Writer: Susan R. Peck, PhD A supplement to To participate in this activity online, go to

2 Oncology Consultations: Improving the Management of Chemotherapy- Induced Nausea and Vomiting (CINV) Initial release date: June 25, 2012 Expiration date: June 25, 2013 Media used: Print monograph with online posttest, evaluation, and request for credit Estimated time to complete this CME activity: 1 hour Copyright: Physicians Education Resource, LLC. Statement of Need Chemotherapy induced nausea and vomiting (CINV) is a major side effect of many common chemotherapy regimens, and is often undertreated. CINV can adversely affect patients quality of life and may impair adherence to prescribed treatment regimens or even lead to withdrawal from potentially curative therapy. Expert guidelines on the prevention and management of CINV have recently been updated based on several new studies, and it is important for clinicians to remain current on the latest standards in order to further improve outcomes for their patients. Learning Objectives Review the recently updated clinical practice guidelines for chemotherapy-induced nausea and vomiting (CINV) Discuss the contributing factors that predispose patients to developing CINV: personal risk factors, chemotherapy emetogenicity category Evaluate clinical data regarding the efficacy and safety of available agents and combination strategies for the prevention and/or treatment of CINV Target Audience This educational activity is directed toward advanced practice nurses and registered nurses involved in the management of patients with cancer. Oncologists, hematologists, physician assistants, nurse practitioners, and other healthcare providers involved in the treatment of patients undergoing chemotherapy may also benefit from this activity. Accreditation and Designation of Credit Statements Dannemiller is approved by the California Board of Registered Nursing, Provider Number 4229, for 1.0 contact hours. RNs outside of California must verify with their licensing agency for approval of this activity. Commercial Support Acknowledgment This activity is supported by an educational grant from Eisai Inc. Faculty Richard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY Rebecca A. Clark-Snow, RN, BSN, OCN Oncology Clinical Nurse Coordinator University of Kansas Cancer Center Westwood, KS Disclosure of Relevant Financial Relationships The following individuals have relevant financial relationships with commercial interests to disclose: Richard J. Gralla, MD is a consultant for Merck & Co., Inc. and Helsinn Group. The following individuals have no relevant financial relationships with commercial interests to disclose: Rebecca Clark-Snow, RN, BSN, OCN; Emily Valko (PER staff); Susan R. Peck, PhD (medical writer); Erin Fletcher (Dannemiller staff). Off-Label/Investigational Use Disclosure This enduring activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the enduring activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/ participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Method of Participation/How to Receive Credit 1. Read the monograph in its entirety. 2. Go to 3. Complete and submit the posttest, evaluation form, and request for credit. 4. Print your Certificate of Credit. This activity is provided free of charge to participants. Educational Partner Contact Information: For questions about this CE activity, please contact: Dannemiller 5711 Northwest Parkway San Antonio, TX Toll-Free: Fax:

3 Oncology Consultations Improving the Management of CINV Case 1 - Presentation and Treatment A 64 year-old man presents with cough and weight loss of 3 kilograms. A computed tomography (CT) scan of the chest reveals a 1.9 cm 2 left upper lobe (LUL) mass, and some enlarged mediastinal lymph nodes. The rest of his workup is entirely negative (including normal 12-channel blood chemistries and complete blood count) with the exception of a positron emission tomography (PET) scan showing increased standardized uptake value (SUV) of 12.3 involving the LUL mass and 1 lymph node area in the mediastinum; all is consistent with the CT findings and with a primary lung cancer. The patient has a long smoking history (quit 6 weeks ago) and has moderate chronic obstructive pulmonary disease (COPD). Percutaneous needle biopsy of the lung lesion reveals squamous cell carcinoma. He is staged as having IIIA squamous cell carcinoma of the left lung. Past medical history additionally includes type 2 diabetes which is well controlled on an oral hypoglycemic drug. He generally consumes about 2 alcoholic drinks per day. His Karnofsky performance status (KPS) is 90%. While several options of therapy exist, his physicians recommend surgical resection. He undergoes video-assisted thoracoscopic surgery (VATS) with left upper lobectomy and mediastinal node dissection, and has complete resection of all known cancer. Final pathology stages the cancer as T1N2M0, Stage IIIA. He is advised to undergo adjuvant chemotherapy. The recommended regimen is vinorelbine 25 mg/m 2 on days 1 and 8 plus cisplatin 75 mg/m 2 on day 1. Cycles are planned for every 3 weeks for a total of 4 cycles. The following anti-emetic regimen is planned: Fosaprepitant 150 mg IV prior to chemotherapy on day 1, plus Palonosetron 0.25 mg IV prior to chemotherapy on day 1 His physician elects not to give dexamethasone due to the history of diabetes He is given a prescription for ondansetron 8 mg for use orally BID starting on day 2, for 3 days, and then as needed Question: How important is it to take a thorough patient history prior to initiating treatment with chemotherapy and an antiemetic regimen? Richard Gralla: First of all, the most important factor in planning for antiemetics is the chemotherapy that patients will be receiving. All the guideline groups agree on that, and the starting point of planning antiemetics is always based on type of chemotherapy. There are other factors that can influence the strategy as well, including medical issues, and known emetic risk factors. (See Tables 1 and 2 for classification of chemotherapy by emetic risk, and Table 3 for patient-specific risk factors.) Rebecca Clark-Snow: I agree with Dr Gralla, and from a nursing perspective, when we see patients in a clinical situation, whether they are new patients, or patients returning for another course of chemotherapy, we always update our patient profiles. In most cases new patients are given a document where they can write down their personal information, including past medical history, medications, surgeries, etc. As oncology nurses who see patients who will be treated with chemotherapy, we ll also probably ask about a past history of alcohol intake. If our patient is a female, we may ask what their obstetrical history is, if they ve had pregnancies, and if they ve had any difficulty with nausea or vomiting associated with those pregnancies. It is important to get a thorough history to see if any background information might possibly influence how they might respond to their treatment. Richard Gralla: It may not be that their past history alters the antiemetic recommendation, but it does tell us something about how well they re likely to do with that regimen, and also where the emetic priority should be among the many teaching messages that patients receive from their treating team. Regarding risk factors, older age and male gender tell you that somebody is at less risk, and if they have a chronic alcohol intake history especially 4 or more drinks per day they re also at less risk. You want to educate the person, but you don t have to harp on it because they re at pretty low risk if you re giving them the right antiemetics. On the other hand, when you get a younger woman with a low alcohol intake history, and for whom emesis during her pregnancies was a real issue, as in Case 2, we know that this person will hopefully do well with what we have, but their chances of having real issues are high up on our list. Question: What do evidence-based guidelines recommend regarding the use of antiemetic therapy for this patient with lung cancer? Richard Gralla: There is quite a bit of consensus among the 4 major evidence-based guideline groups (Multinational Association of Supportive Care in Cancer [MASCC], American Society of Clinical Oncology [ASCO], European Society for Medical Oncology [ESMO], and National Comprehensive Cancer Network [NCCN]). They re so similar because they are all based on the same data. Three of the groups are very strongly based on evidence, while the fourth group considers evidence strongly, but bases their recommendations on consensus. If practice groups have their own local guidelines, that s fine as long as they don t disagree with the evidence-based international guidelines. If they disagree, then the evidence must be presented as to why to vary from the international and national guidelines. (See Tables 4, 5, and 6 for highlights of the expert guidelines for the prevention of acute/delayed CINV.) Now, if we take Case 1, a patient getting initial cisplatin, an NK-1 receptor antagonist, and palonosetron were advised those are indeed consistent with all the guidelines. The problem here is that since the patient has diabetes, the physician has elected to avoid corticosteroids because the physician is aware that this will increase the patient s blood sugar. However, that is not consistent with any guideline. Instead, it can be argued that the person with diabetes is at important risk if they have emesis, meaning impact on how to control their anti-diabetes medicine if they can t take food or fluids, and it becomes a real problem. So most individuals advise the same regimen for the diabetic but enhanced training about monitoring their diabetes during their chemotherapy period. Rebecca Clark-Snow: This is a scenario that we see on a daily basis. Many patients do have diabetes and need to receive the most appropriate antiemetic regimen, in addition to carefully monitoring their chemistries. Oncology Consultations 3

4 [NCCN 2012] Table 1. Emetic Risk of Various Intravenous Chemotherapeutic Agents According to the NCCN Guidelines Emetic Risk Agents High ( >90%) AC combination (doxorubicin or epirubicin with cyclophosphamide) Carmustine (>250 mg/m 2 ) Cisplatin 50 mg/m 2 Cyclophosphamide >1500 mg/m 2 Dacarbazine Epirubicin >90 mg/m 2 Ifosfamide 10 g/m 2 Mechlorethamine Streptozocin Moderate (30%-90%) Aldesleukin >12-15 MIU/m 2 Amifostine >300 mg/m 2 Arsenic trioxide Azacitidine Bendamustine Busulfan Carboplatin Carmustine 250 mg/m 2 Cisplatin <50 mg/m 2 Clofarabine Cyclophosphamide 1500 mg/m 2 Cytarabine >200 mg/m 2 Dactinomycin Daunorubicin Doxorubicin 60 mg/m 2 Epirubicin 90 mg/m 2 Idarubicin Ifosfamide <10 g/m 2 Interferon alfa >10 MIU/m 2 Irinotecan Melphalan Methotrexate 250 mg/m 2 Oxaliplatin Temozolomide Low (10%-30%) Amifostine 300 mg/m 2 Aldesleukin 12 MIU/m 2 Cabazitaxel Cytarabine (low dose) Docetaxel Doxorubicin (liposomal) Eribulin Etoposide 5-Fluorouracil Floxuridine Gemcitabine Interferon alfa (>5 and <10 MIU/m 2 ) Ixabepilone Methotrexate (>50 to <250 mg/m 2 ) Mitomycin Mitoxantrone Paclitaxel Paclitaxel albumin Pemetrexed Pentostatin Pralatrexate Romidepsin Thiotepa Topotecan Minimal (<10%) Alemtuzumab Asparaginase Bevacizumab Bleomycin Bortezomib Cetuximab Chlorambucil (oral) Cladribine Cytarabine <100 mg/m 2 Decitabine Denileukin diftitox Dexrazoxane Fludarabine Interferon alfa ( 5 MIU/m 2 ) Ipilimumab Methotrexate <50 mg/m 2 Nelarabine Ofatumumab Panitumumab Pegaspargase Peginterferon Rituximab Temsirolimus Trastuzumab Valrubicin Vinblastine Vincristine Vinorelbine Patients are now able to do home monitoring, and let us know exactly how their diabetes is affected by receiving dexamethasone as part of their antiemetic regimen. In many cases, it s really not a problem for patients to receive a corticosteroid and have a diagnosis of diabetes as well, but it is always in the patient s best interest to continue close follow-ups. Richard Gralla: The physician and nurse need to decide on how the patient should alter their diabetic medicine during this period depending on what happens to the blood sugar, which might be different than what they would do 99% of the time, but in these 3 or 4 days might be pretty important. Rebecca Clark-Snow: I ll add that this is a good teaching moment between a nurse and a patient, to inform them that their glucose may be elevated while they re taking the corticosteroid, and not to be overly alarmed, that in most instances it s something that can be managed by their physician and nurse. Question: Do the guidelines indicate any preference regarding their recommendations for fosaprepitant versus aprepitant? Richard Gralla: In most instances the guidelines simply say an NK-1 antagonist, but ASCO updated their guidelines in 2011 to say that for highly emetic circumstances, such as this cisplatin case, they re equivalent. [Basch 2011] (See Sidebar 1. NK-1 Receptor Antagonists for the Prevention of Acute/Delayed CINV) So one can use fosaprepitant 150 mg IV, which is an elevated dose and is indicated for just 1 day, or one can use the 3-day oral aprepitant regimen if so desired. Those are interchangeable and equivalent, and ASCO states that very well. NCCN more or less says the same thing. [NCCN 2012] MASCC and ESMO are in the process of updating their guidelines to include fosaprepitant. Question: Are there differences in the guidelines regarding the use of the 5-HT 3 receptor antagonists? Richard Gralla: There are. All of the guideline groups recommend palonosetron as the preferred 5-HT 3, or serotonin type-3 receptor antagonist, for chemotherapies with a moderate emetic risk. (Boasch 2011; Roila 2010; NCCN 2012] Only NCCN has specifically recommended palonosetron for both high and moderate emetic risk chemotherapies. [NCCN 2012] The other guideline groups basically say it s your choice of a serotonin antagonist with highly emetic regimens. (See Sidebar 2. Comparative Efficacy of First and Second Generation Serotonin 5-HT3 Receptor Antagonists) Question: This patient also received a prescription for ondansetron for days 2 and 3. Is a follow-on 5-HT 3 antagonist generally recommended? Richard Gralla: This is probably the area where people in practice differ most from the guidelines. As a general rule, none of the guideline groups recommend follow-on 5-HT 3 antagonists of any sort for delayed emesis. The reason for that dates more than anything from a 2005 meta-analysis published in JCO that says that if you use a follow-on serotonin antagonist days 2 to 5, you only get a 2.6% boost if you re using corticosteroids as well, as the guidelines have recommended. [Geling 2005] So if you only get a 2.6% benefit, which was not statistically significant, then the guideline groups have said it s not worth it. Looking at ondansetron specifically, and also dolasetron, which is not used too much anymore, the FDA has asked for more studies with these agents regarding their effect on prolonging the QTc interval. ASCO mentions in their updated guidelines that the FDA has this under review and that physicians need to be aware of it. [Basch 2011] 4 Oncology Consultations

5 [NCCN 2012] Table 2. Emetic Risk of Various Oral Chemotherapeutic Agents According to the NCCN Guidelines Emetic Risk Moderate to High Minimal to Low Agents Altretamine Busulfan 4 mg/day Cyclophosphamide 100 mg/m 2 /day Estramustine Bexarotene Busulfan <4 mg/day Capecitabine Chlorambucil Cyclophosphamide <100 mg/m 2 /day Dasatinib Erlotinib Everolimus Fludarabine Gefitinib Hydroxyurea Imatinib Lapatinib Lenalidomide Etoposide Lomustine (single day) Procarbazine Temozolomide >75 mg/m 2 /day Melphalan Mercaptopurine Methotrexate Nilotinib Pazopanib Sorafenib Sunitinib Temozolomide 75 mg/m 2 /day Thalidomide Thioguanine Topotecan Tretinoin Vandetanib Vorinostat QTc prolongation is not really much of an issue with granisetron, and is not even in the label with palonosetron. Rebecca Clark-Snow: In most clinical situations when patients receive these medications, we don t routinely get electrocardiograms, and just as Dr Gralla mentioned, we have a long history of being able to use these medications safely, and we ll continue to do so. Table 3. Patient-Specific [NCCN 2012] Risk Factors for CINV Increased Risk Sex (Female) Age (<50 years old) History of motion sickness Previous episodes of nausea and vomiting Decreased Risk History of chronic alcoholism Richard Gralla: I think it s important to say that none of the serotonin antagonists are indicated as follow-on medicines for delayed emesis, and second, no oncologist that I know thinks that electrocardiograms are warranted for any of these agents you would have to have some other reason to order one. Another issue regarding ondansetron that I think nurses and physicians need to be aware of is that most hospital-based pharmacies pay very little for ondansetron. But when you send your patient out to the retail pharmacy, the charge is very high. So be aware of these issues because they have real impacts on your patients in terms of copay or in terms of running through whatever is covered for retail drugs. Question: How can nurses assist patients with recording their experiences at home? Rebecca Clark-Snow: This is a significant issue for nurses and patients. Nurses are so busy that we very rarely have an opportunity to follow up with patients after they ve left the clinic or call them for several days afterwards to see how they re doing. In most instances we rely on patients to provide that information by either calling us if they re having a problem, or when we see them for their return visit, we learn that in fact they ve had either a really good response or they ve had some issues with control. So I think it is important to give patients all of the information they will need in the form of patient teaching, but also to provide them with a tool if necessary. There is a very easy-to-use tool that s been developed by MAS- CC for nurses and physicians to administer to patients, who with proper instruction will be able to document the number of emetic episodes, as well as the degree of nausea they ve had while at home. The MASCC Antiemesis Tool (MAT) provides a format for patients beginning 24 hours after chemotherapy and continuing for 4 days after chemotherapy to keep track of just how well they did post treatment. Patients are encouraged to bring the completed MAT to their next clinic visit, and share this important information with their nurses and physicians, who can make changes if necessary to their antiemetic regimen for the next cycle of chemotherapy. Richard Gralla: Every doctor and nurse can get this on the web. It s a free download available at: PageId=88036 Not only is this something that can be printed out or given electronically to patients, but it s available in multiple languages including the most common languages in the United States and in Canada. And it also can be used as a continuous improvement project if a nursing group wants to do so. It even comes with the spreadsheet. One should also watch the MASCC website regarding the MAT because an app for this is likely to be available soon. Rebecca Clark-Snow: This tool has been validated and is reliable. Several individuals including physicians and nurses developed the MAT, hoping that it would provide useful information to assist with supportive care decisions. Question: Are there any other concerns or issues regarding Case 1 that you would like to mention? Richard Gralla: Regarding the NK-1 antagonists, the only 2 that are commercially available are aprepitant and its prodrug, fosaprepitant. Again, the recent study by Grunberg et al showed that the 1-day dose of 150 mg of fosaprepitant is equivalent to the 3-day regimen of aprepitant. [Grunberg 2011] There are also other investigational NK-1 antagonists. These include casopitant, where the research seems to have slowed down, and the drugs netupitant and rolapitant which are now in phase 3 trials. One other issue I d like to bring up on Case 1 is that this patient was treated with cisplatin, which is the preferred platinum drug in adjuvant therapies, although some controversy exists as to which platinum can be used in the treatment of patients with advanced disease. While meta-analyses favor cisplatin, sometimes doctors favor carboplatin. The question is, if you re going to use carboplatin, do you need to use 3 antiemetic agents or not? So far the guideline groups say that a 5-HT 3 antagonist and a corticosteroid are sufficient, but one must be aware of a recent randomized study by Rapoport et al that included 848 patients, which did show a similar advantage of approximately 8% to 13% absolute benefit with regard to complete control if one uses 3 drugs, even in carboplatin circumstances, although the guideline groups have not yet made this recommendation. [Rapoport 2010] Oncology Consultations 5

6 Case 2 Presentation and Treatment A 39-year-old woman presents with invasive ductal carcinoma after a screening mammogram detected a 1.3-cm abnormality. She has been remarkably healthy with no significant past medical problems. She is G2P2A0, with her first child born when she was 23 years of age. Her pregnancies proceeded to term without complications, with the exception of fairly marked emesis of pregnancy in both cases. She has no family history of breast cancer. She is a never smoker, rarely drinks any alcohol, and is not obese. The cancer was resected by lumpectomy; sentinel node sampling was negative. The tumor was ER+ / PR+ and HER 2. She recovered well from the surgical procedure without complications. Based on the above findings, her physicians recommended doxorubicin + cyclophosphamide (AC) with 4 cycles planned, followed by paclitaxel for 4 cycles as adjuvant chemotherapy, which the patient followed. The anti-emetic regimen recommended consisted of: ` Palonosetron 0.25 mg IV on day 1, plus 10 mg IV on day 1 (for acute emesis) She was also given a prescription for granisetron 1 mg PO to begin the night of chemotherapy and every 12 hours for 3 days (for delayed emesis prevention) Question: What is the emetogenic potential of an AC-based regimen for this patient? What are some concerns? Rebecca Clark-Snow: I believe it s well known, and most of the major oncology groups have noted, that AC is a highly emetogenic chemotherapy treatment for women with breast cancer, who need to receive the most appropriate antiemetic regimen, which would be the combination of an NK-1 antagonist, a serotonin antagonist, and a corticosteroid. Richard Gralla: This is a change over the past several years, but all major international guideline groups say that women treated with AC should be treated from the first cycle on with the triple therapy just outlined. ASCO and NCCN have classified AC-type chemotherapy, that is, chemotherapy based on an anthracycline and cyclophosphamide, as highly emetic. [Basch 2011; NCCN 2012] MASCC and ESMO recommend the same 3-drug treatment, but put it in a separate category called AC chemotherapy. [Roila 2010] All of the guidelines groups say first cycle, every cycle, one should prescribe the triple regimen. It s not something to wait and see on, and it s not an area where there s disagreement among the evidence-based guideline groups. Question: How would this patient s characteristics affect risk and how do you factor these in when deciding on a prophylactic strategy? Richard Gralla: This woman is really at quite high risk. She s relatively young. She is, of course, female. And she has a low alcohol intake history. And to make matters even more risky for her, she had emesis during both of her pregnancies. Because of that, all the monitoring and education that Rebecca discussed in the last case really need to be brought to bear on this patient. Question: What are the recommendations to prevent delayed emesis? Richard Gralla: The guidelines from all of the groups say that if you followed the proper day-1 recommendations you don t need to continue with the serotonin antagonist after day 1. Again, this is partially based on the meta-analysis that I quoted before and on individual clinical trials. Remember, while the serotonin antagonists are quite well tolerated, the headache and especially the constipation are still bothersome to patients. It s not that we don t know how to treat those issues, but with supportive care agents, we like not to have to support the supportive care agent whenever possible. Some recent trials, one by Aapro et al, looked at giving the steroids on day 1 but not giving follow-up steroids. And the control for the patient was very, very similar. [Aapro 2010] So for AC-type chemotherapy emerging literature may indicate that follow-on corticosteroids may end up being optional. Now while I agree with those findings, in this case before we have more evidence, with the very high personal characteristics of risk that this patient brings to the table, I probably would continue the corticosteroids. Sidebar 1 NK-1 Receptor Antagonists for the Prevention of Acute/Delayed CINV NK-1 receptor antagonists have been shown to reduce emesis triggered by a variety of stimuli by interfering with the action of Substance P, a regulatory peptide in the central nervous system and the gastrointestinal tract. The first NK-1 receptor antagonist developed was the oral drug aprepitant. Two randomized clinical studies compared adding aprepitant on a 3-day schedule with standard therapy (day 1, ondansetron + dexamethasone; days 2-4, dexamethasone) in patients receiving a cisplatinbased chemotherapy regimen. [Hesketh 2003; Poli-Bigelli 2003] The addition of aprepitant significantly improved emesis efficacy rates in both the acute and delayed phases compared with standard treatment. However, there was no significant improvement in nausea. In another study of 866 patients with breast cancer treated with an anthracycline plus cyclophosphamide, the addition of aprepitant to standard therapy (odansetron plus dexamethasone) significantly improved complete response rates (51% versus 42%, P =.015) and acute phase complete response rates (defined as no vomiting or use of rescue agents; 76% versus 69%, P =.034), but no difference was observed in the delayed phase. [Warr 2005] In addition, although significantly more patients in the aprepitant arm reported no vomiting (76% vs 59%; P <.001), no difference was observed in the use of rescue medication. Fosaprepitant is a prodrug of aprepitant, and is available as an intravenous formulation. In a randomized equivalency study that was conducted in 2322 patients receiving cisplatin-based chemotherapy a single intravenous dose of fosaprepitant demonstrated equivalent antiemetic protection compared with the standard 3-day oral aprepitant schedule. [Grunberg 2011] References Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--ease. J Clin Oncol. 2011;29(11): Hesketh PJ, Grunberg SM, Gralla RJ, et al; Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22): Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Aprepitant Protocol 054 Study Group. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12): Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapyinduced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12): Oncology Consultations

7 Table 4. Expert Guideline Recommendation Highlights for Managing Acute/Delayed CINV: High Emetic Risk Chemotherapy NCCN [NCCN 2012] ASCO [Basch 2011] [Roila 2010] MASCC/ESMO 3-Drug Regimen: NK-1 antagonist (aprepitant days 1-3 or fosaprepitant day 1 only) 5-HT 3 receptor antagonist Palonosetron is the preferred 5-HT3 receptor antagonist because of higher receptor affinity, longer half-life, and efficacy in preventing both acute and delayed emesis Lorazepam days 1-4 may also be considered Histamine 2 blocker or proton pump inhibitor may be beneficial in some cases to prevent dexamethasone-induced gastritis 3 Drug Regimen: NK-1 antagonist (aprepitant days 1-3 or fosaprepitant day 1 only) (days 1-3 or 1-4) 5-HT 3 receptor antagonist (day 1 only) Anthracycline plus cyclophosphamide-based chemotherapy now classified as highly emetogenic 3 Drug Regimen: NK-1 antagonist (aprepitant or fosaprepitant) 5-HT 3 receptor antagonist (single dose prior to chemotherapy) Regarding 5-HT 3 receptor antagonists, the panel noted: The lowest tested, fully effective dose should be used No schedule is better than a single dose given before chemotherapy Adverse events are comparable IV and oral formulations are equally effective and safe First-generation agents show comparable efficacy. Palonosetron has been shown to be more protective with regard to emesis, but studies are needed to demonstrate superiority when combined with an NK-1 receptor antagonist Table 5. Expert Guideline Recommendation Highlights for Managing Acute/Delayed CINV: Moderate Emetic Risk Chemotherapy NCCN [NCCN 2012] ASCO [Basch 2011] [Roila 2010] MASCC/ESMO Day 1 Regimen: 5-HT 3 receptor antagonist plus dexamethasone with or without an NK-1 antagonist Days 2 and 3, 1 of the following 3 regimens: 5-HT 3 antagonist (ondansetron, granisetron or dolasetron; palonosteron is not given on days 2-3) Aprepitant with or without dexamethasone Palonosetron is the preferred 5-HT 3 receptor antagonist because of higher receptor affinity, longer half-life, and efficacy in preventing both acute and delayed emesis 2-Drug Regimen: Palonosetron (day 1 only) (days 1-3) If palonosetron is unavailable, other first generation 5-HT 3 receptor antagonists may be substituted. Administration of dexamethasone or a 5-HT 3 receptor antagonist is recommended for delayed CINV For non-ac-based chemotherapy, a 2-drug regimen consisting of palonosetron plus dexamethasone is recommended. AC-based chemotherapy is recognized as a particularly potent emetogenic regimen, and prophylactic therapy with the 3-drug regimen recommended for high-emetic-risk chemotherapies should be used. If aprepitant is unavailable, palonosetron plus dexamethasone is recommended. Prophylactic therapy for delayed emesis should be used if the risk is significant: Multiday dexamethasone is recommended for non-ac chemotherapy when palonosetron is used for acute prophylaxis Aprepitant is recommended for patients with breast cancer receiving AC-based chemotherapy Table 6. Expert Guideline Recommendation Highlights for Managing Acute/Delayed CINV: Low or Minimal Emetic Risk Chemotherapy NCCN [NCCN 2012] ASCO [Basch 2011] [Roila 2010] MASCC/ESMO For low-emetic-risk chemotherapy, dexamethasone, metoclopramide or prochlorperazine are recommended No routine prophylaxis needed for minimal-emetic-risk; dexamethasone, metoclopramide or prochlorperazine may be used if CINV develops is suggested for low emetic risk chemotherapy No antiemetic is recommended for minimal-emetic-risk chemotherapy Single agent therapy is recommended when the emetic risk level is low (eg, dexamethasone, 5-HT 3 receptor antagonist, or dopamine receptor antagonist). However, level of evidence and confidence for this recommendation is low No prophylactic antiemetic therapy is recommended for chemotherapy with minimal emetic risk. Single-agent prophylaxis may be used for subsequent cycles if nausea and/or vomiting does occur Question: What would you do if this patient developed breakthrough or refractory nausea and vomiting? Rebecca Clark-Snow: The recommendation is to reevaluate the emetic risk, including the patient s disease status, if they have any concurrent illnesses, and take a good look at what medication she is receiving. It s possible that there may be another medication such as a narcotic that could be causing the patient to have nausea and vomiting aside from the chemotherapy. Then go through all the steps that we would normally go through as far as identifying the best antiemetic. After it s been determined that the best regimen is being given for the emetic risk, we can consider possibly adding some adjunctive medication such as lorazepam or alprazolam. One of the medications that some physicians are using, or considering using, is olanzapine. Or perhaps substitute high-dose intravenous metoclopramide instead of the serotonin antagonist or add a dopamine antagonist. So there are several different things that can be looked into, and reevaluated in order to make sure that this patient does have a better outcome as far as her control of nausea and vomiting is concerned. Richard Gralla: Of course, when I find out this patient didn t do well, I m very concerned. As Rebecca said, go back and find out if there is something else going on such as other medications, bronchodilators, other things that could be contributing. What was the pattern of emesis? Was it not typical for the chemotherapy? If the patient had ovarian cancer instead, could there be an intestinal obstruction, or something else going on? Also look not only at what medications were recommended, but what did she actually take? Often when patients do well on day 1, they ll say they just didn t want to take any more medicines, and who Oncology Consultations 7

8 Sidebar 2. Comparative Efficacy of First and Second Generation Serotonin 5-HT 3 Receptor Antagonists There are currently four 5-HT 3 antagonists available in the United States. The firstgeneration antagonists (ie, dolasetron, granisetron, and ondansetron) exhibit similar efficacy, while the newer agent palonosetron has shown an increased ability to control increased CINV symptoms. [Roila 2010; Basch 2011, NCCN 2012] Headache is the most common adverse event observed with all agents. Palonosetron has been compared with the first-generation 5-HT 3 receptor antagonists in several randomized trials. In 1 study, palonosetron (0.25 mg or 0.75 mg intravenously) was compared with dolasetron (100 mg intravenously) in 569 patients receiving moderately emetogenic chemotherapy. [Eisenberg 2003] Overall complete response rates were significantly higher for both doses of palonosetron (0.25 mg: 46%, P =.021; 0.75 mg: 47%, P =.012) compared with dolasetron (34%). Delayed complete response rates were also significantly higher with both doses of palonosteron, but only the 0.25 mg dose was superior in the acute phase. A second randomized trial compared ondansetron (32 mg) to palonosetron at the same 2 doses in patients receiving moderately emetogenic chemotherapy. [Gralla 2003] In this trial, the complete response rate (no emetic episode and no rescue medication) was superior with palonosetron at the 0.25 mg dose (69%, P <.001), but not the 0.75 mg dose (59%, P =.1192), compared with ondansetron (50%). Palonosteron (0.25 mg and 0.75 mg) has also been compared with ondansetron (32 mg) in patients receiving highly emetogenic chemotherapy. [Aapro 2006] Two-thirds of the 667 patients in this study received concomitant dexamethasone. Overall, acute and delayed complete response rates were statistically equivalent between palonosetron and ondansetron treatment arms in the intent to treat analysis. In the subgroup of patients who also received dexamethasone, however, complete response rates were significantly higher with palonosetron compared with ondansetron overall (41% vs 25%; P =.005). Palonosteron was also superior in the delayed phase (42% vs 29%; P =.021). Finally, palonosetron (0.75 mg) plus dexamethasone was compared with granisetron (40 mcg/kg) plus dexamethasone in 1143 Japanese patients undergoing treatment with highly emetogenic chemotherapy (cisplatin or anthracycline/ cyclophosphamide). [Saito 2009] During the acute phase, the complete response rate was similar between arms (75% for palonosetron versus 73% for granisetron), but palonosteron significantly improved rates during the delayed phase (57% vs 44.5%; P <.0001). References Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17(9): Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31): Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapyinduced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, singledose trial versus dolasetron. Cancer. 2003;98(11): Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10): NCCN Clinical Practice Guidelines inoncology: Antiemesis. V National Comprehensive Cancer Network Web site. antiemesis.pdf. Accessed May 9, Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010; 21(suppl 5): v232-v243. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10(2): can blame them? But nonetheless the preventive role of the delayed emesis medications is so important. So did the patient really take what we had advised and did we communicate well what they should have been taking? Now, once all those situations are true, but the patient still has emesis, then there are some other considerations. Many people like to use benzodiazepines even in cycle 1 because they reduce anxiety. They re not really antiemetics, but they are adjuncts as part of supportive care. And this patient is at risk if she didn t do well in the first cycle of developing anticipatory emesis. The MASCC website is an excellent source of publications that are free downloads for each of these situations including anticipatory emesis. I don t recommend changing antiemetics entirely, but looking in to proper alterations. You want to know how much emesis she had. One episode? Two? Three? Because if she were not getting antiemetics at all, or if the antiemetics weren t helping at all, the average number of episodes would be 10 to 15. So we don t want to necessarily throw out the lessthan-perfect regimen if we are not certain as to how to improve upon it. There are investigative studies ongoing using the anti-psychotic drug olanzapine, as mentioned by Rebecca Clark-Snow, which are worth our attention to see whether they can be additive agents, but of course this is still in the investigative stage even though the drug is generically available. And then there are small steps. I don t treat such patients if they have problems on Thursdays or Friday. Patients with problems on the prior chemotherapy cycles are those that are particularly called the next day by our oncology nurses. There s a recent prospective observational study called the PEER (Pan European Emesis Registry) Study that indicates that if patients follow guidelines, they do significantly better and they have less of a need for an urgent care visit. [Aapro 2012]. This benefit in better contolled emesis also extended to better control of nausea as well, in those patients who received antiemetics consistent with evidence-based guidelines. References Aapro M, Fabi A, Nolè F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21(5): Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER) [published online ahead of print March ]. Ann Oncol [abstract] Accessed May 9, Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31): Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6): Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapyinduced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--ease. J Clin Oncol. 2011;29(11): NCCN Clinical Practice Guidelines inoncology: Antiemesis. V National Comprehensive Cancer Network Web site. Accessed May 9, Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4): Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232-v Oncology Consultations Physicians Education Resource, LLC.

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Guideline Update on Antiemetics

Guideline Update on Antiemetics Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction

More information

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,

More information

MASCC Guidelines for Antiemetic control: An update

MASCC Guidelines for Antiemetic control: An update MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,

More information

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of

More information

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

More information

Managements of Chemotherpay Induded Nausea and Vomiting

Managements of Chemotherpay Induded Nausea and Vomiting REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer

More information

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg

More information

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV 09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,

More information

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guidelines for the Use of Anti-Emetics with Chemotherapy Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting

More information

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:

More information

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders 1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive

More information

Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting

Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University

More information

Northern Cancer Alliance

Northern Cancer Alliance Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2

More information

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet ) Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) 09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT

More information

ANTIEMETIC GUIDELINES: MASCC/ESMO

ANTIEMETIC GUIDELINES: MASCC/ESMO Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:

More information

Subject: Palonosetron Hydrochloride (Aloxi )

Subject: Palonosetron Hydrochloride (Aloxi ) 09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Corporate Medical Policy

Corporate Medical Policy Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure

More information

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.

More information

Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)

Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David

More information

Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines

Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information

More information

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this

More information

Why Patients Experience Nausea and Vomiting and What to Do About It

Why Patients Experience Nausea and Vomiting and What to Do About It Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer

More information

Patient-Centered Management of Chemotherapy-Induced Nausea and Vomiting

Patient-Centered Management of Chemotherapy-Induced Nausea and Vomiting Clear and accurate communication between patients and health care teams is the key to successfully controlling chemotherapy-induced nausea and vomiting. Roseate Spoonbill_2005. Photograph courtesy of Henry

More information

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date: Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Tools and Resources for Self-Study and Patient Education

Clinical Tools and Resources for Self-Study and Patient Education Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational

More information

Supportive care session 1:

Supportive care session 1: Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives

More information

Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients

Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018

More information

MOLECULAR AND CLINICAL ONCOLOGY 2: , 2014

MOLECULAR AND CLINICAL ONCOLOGY 2: , 2014 MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced

More information

ATTUALITÀ NEL CONTROLLO DELL EMESI

ATTUALITÀ NEL CONTROLLO DELL EMESI ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions

More information

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK

More information

Clinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17

Clinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date: Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

Update on antiemetics, what is new and future directions. Karin Jordan University of Halle

Update on antiemetics, what is new and future directions. Karin Jordan University of Halle Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day

More information

Clinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies: VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic

More information

Antiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue

Antiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration

More information

Management of Nausea and Vomiting

Management of Nausea and Vomiting June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most

More information

Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care

Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Presented as a Live Webinar Wednesday, April 13, 2016 12:00 p.m. 1:00 p.m. ET Tuesday,

More information

Prophylaxis and Management of Chemotherapy-Induced Nausea and Vomiting: A Comparison of How the Experts Practice

Prophylaxis and Management of Chemotherapy-Induced Nausea and Vomiting: A Comparison of How the Experts Practice The following is an edited transcript of a CME/CE- certified video series and is intended for informational purposes only. To receive credit for the activity, participants must view the videos online at

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Drug: Aprepitant (Emend ) Date of Review: 4/01/10

Drug: Aprepitant (Emend ) Date of Review: 4/01/10 CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010

More information

Chemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control

Chemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting

More information

Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto

Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the

More information

Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice

Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity

More information

Published Ahead of Print on September 26, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology

Published Ahead of Print on September 26, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology Published Ahead of Print on September 26, 2011 as 10.1200/JCO.2010.34.4614 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.34.4614 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C

More information

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org Continue Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that

More information

PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER

PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER June 2004 PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 DELAYED EMESIS WORKING

More information

TRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)

TRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation) The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron

More information

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

Job title: Consultant Pharmacist/Advanced Practice Pharmacist Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced

More information

Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting

Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Sayantani Ghosh, Saugat Dey Corresponding author: Sayantani Ghosh (ghoshsayantani@rediffmail.com) Correspondence concerning

More information

clinical practice guidelines

clinical practice guidelines clinical practice guidelines Annals of Oncology 21 (Supplement 5): v232 v243, 2010 doi:10.1093/annonc/mdq194 Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced

More information

Overview of the neurokinin-1 receptor antagonists

Overview of the neurokinin-1 receptor antagonists Editorial Page 1 of 6 Overview of the neurokinin-1 receptor antagonists Rudolph M. avari Division of Hematology Oncology, School of Medicine, University of Alabama Birmingham, Birmingham, AL, USA Correspondence

More information

Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A

More information

Trust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults

Trust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:

More information

Organizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD

Organizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY PERUGIA, March 29-31, 2004 Organizing and Overall Meeting

More information

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference Annals of Oncology 17: 20 28, 2006 doi:10.1093/annonc/mdj078 Published online 28 November 2005 Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic

More information

Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017

Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors

More information

SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it

SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI   nicsonet.it SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni

More information

MASCC/ESMO ANTIEMETIC GUIDELINE 2016

MASCC/ESMO ANTIEMETIC GUIDELINE 2016 1 MASCC/ESMO ANTIEMETIC GUIDELINE 2016 Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex

More information

Chemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting

Chemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting CHAPTER 12 Chemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting Elizabeth Blanchard T he ability of chemotherapy to cause nausea and vomiting is legendary and remains a widespread

More information

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master

More information

The AngCN Antiemetic Guidelines

The AngCN Antiemetic Guidelines The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction

More information

Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced

More information

Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue

Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2015 NCCN.org Continue Version 1.2015, 04/01/15 National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important

More information

Emetogenicity level 1. Emetogenicity level 2

Emetogenicity level 1. Emetogenicity level 2 Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea

More information

PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK

PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior

More information

Medicare Part C Medical Coverage Policy

Medicare Part C Medical Coverage Policy Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications

More information

An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy

An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy 2014 An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy Chepsy C Philip 1*, Biju George 1 1 Department of Clinical Haematology, CMC Vellore, Tamil Nadu, India. ARTICLE INFO Article type:

More information

Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients

Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department

More information

Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy

Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3

More information

Original. Key words : breast cancer, chemotherapy-induced nausea and vomiting, quality of life, Functional Living Index Emesis

Original. Key words : breast cancer, chemotherapy-induced nausea and vomiting, quality of life, Functional Living Index Emesis Showa Univ J Med Sci 30 2, 285 296, June 2018 Original The Impact on Quality of Life of Highly Effective Antiemetic Therapy among Breast Cancer Patients Receiving Anthracycline Plus Cyclophosphamide-based

More information

Chemotherapy-induced nausea and vomiting (CINV)

Chemotherapy-induced nausea and vomiting (CINV) At a Glance Practical Implications e54 Author Information e57 Full text and PDF 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors Original Research Claudio Faria, PharmD,

More information

Management of chemotherapyinduced nausea and vomiting

Management of chemotherapyinduced nausea and vomiting p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting

More information

Clinical Roundtable Monograph

Clinical Roundtable Monograph Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology March 2015 New and Emerging Therapeutic Options for the Management of Chemotherapy-Induced Nausea and Vomiting Discussants Lee S.

More information

Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue

Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2016 NCCN.org Continue Version 1.2016 03/15/16 National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN

More information

Pediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives

Pediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees

More information

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens 569 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(5): 569-575. doi: 10.7150/jca.13637 Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk

More information

Managing Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting

Managing Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe

More information

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong

More information

Review Article Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors

Review Article Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 309601, 7 pages http://dx.doi.org/10.1155/2015/309601 Review Article Prevention of Nausea and Vomiting in Patients Undergoing

More information

ECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy

ECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy ECN Protocol Book Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Name of person presenting document: Reason f document development: Names of development team: Specify groups

More information

Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Tamara Goldberg, PharmD, BCPS; Brooke Fidler, PharmD; and Stephanie Cardinale,

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018

More information

Chemotherapy Induced Nausea and Vomiting

Chemotherapy Induced Nausea and Vomiting Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting

More information

Sue Faulkner, BSN RN OCN October 18, 2017 Updates from Congress 2017

Sue Faulkner, BSN RN OCN October 18, 2017 Updates from Congress 2017 Report: Occurrence and Implications of Chemotherapy-Induced nausea and Vomiting (CINV): Implications for the Oncology Nurse Practitioner to Optimize Patient Outcomes Sue Faulkner, BSN RN OCN October 18,

More information

ORIGINAL ARTICLE. Ralph Boccia & Steven Grunberg & Edwin Franco-Gonzales & Edward Rubenstein & Daniel Voisin

ORIGINAL ARTICLE. Ralph Boccia & Steven Grunberg & Edwin Franco-Gonzales & Edward Rubenstein & Daniel Voisin Support Care Cancer (2013) 21:1453 1460 DOI 10.1007/s00520-012-1691-5 ORIGINAL ARTICLE Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea

More information

Antiemetics: Guidelines, Interactions and more.

Antiemetics: Guidelines, Interactions and more. Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees

More information

Antiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy

Antiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record

More information

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or

More information

Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Geng Song, Qian He, Fanfan Li, and Nianfei Wang Department of Oncology, The Second Affiliated

More information